Biologic therapies for psoriasis, including TNF-α inhibitors, IL-17 inhibitors, and IL-23 inhibitors, are antibody-based treatments that have demonstrated substantial therapeutic efficacy. The gene discussed is IL17A; the disease is psoriasis.